id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC6616248
core_pubmed_pmc
Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study
Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study Abstract Purpose: There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven parti...
PMC6349757
core_pubmed_pmc
Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding
Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding Abstract Abstract Isoniazid is a firs...
PMC6509210
core_pubmed_pmc
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma Abstract Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brainstem tumour, with a quarter of patients harbouring somatic mutations in ACVR1 , encoding the serine/threonine kinase ALK2. Despite...
PMC10455840
core_pubmed_pmc
A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species
A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species Abstract Abstract Antifungals are used in exotic avian and reptile species for the treatment of fungal diseases. Dose extrapolations across species are common due to lack of species-specific pharmacological data. This may...
PMC10777433
core_pubmed_pmc
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants Abstract Abstract Bersiporocin, a potent and selective prolyl‐tRNA synthetase inhibitor, is expected to show a synergistic effect with pirfenidone or nintedanib in patients w...
PMC7785128
core_pubmed_pmc
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review Abstract Tigecycline is unique glycylcycline class of semisynthetic antimicrobial agents developed for the treatment of polymicrobial infections caused by multidrug-resistant Gram-positive and Gra...
PMC7696167
core_pubmed_pmc
Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa : A Study on Population Pharmacokinetics with Monte Carlo Simulations
Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with Pseudomonas aeruginosa : A Study on Population Pharmacokinetics with Monte Carlo Simulations Abstract Roscovitine (Seliciclib), a new protein kinase inhibitor, was administered orally to adult patients wit...
PMC10948865
core_pubmed_pmc
Factors influencing JUUL e-cigarette nicotine vapour-induced reward, withdrawal, pharmacokinetics and brain connectivity in rats: sex matters
Factors influencing JUUL e-cigarette nicotine vapour-induced reward, withdrawal, pharmacokinetics and brain connectivity in rats: sex matters Abstract Abstract Though vaping likely represents a safer alternative to smoking, it is not without risks, many of which are not well understood, especially for vulnerable popula...
PMC6001839
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation
Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation Abstract Objective We investigated the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of linezolid in patients who had suffered cer...
PMC8063233
core_pubmed_pmc
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study Abstract Abstract Context Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may enhance serum uric acid (sUA) lowerin...
PMC7116968
core_pubmed_pmc
Panax ginseng and Panax quinquefolius : From pharmacology to toxicology
Panax ginseng and Panax quinquefolius : From pharmacology to toxicology Abstract The use of Panax ginseng and Panax quinquefolius in traditional Chinese medicine dates back to about 5000 years ago thanks to its several beneficial and healing properties. Over the past few years, extensive preclinical and clinical eviden...
PMC4816246
core_pubmed_pmc
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects Abstract OBJECTIVES: To evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-438 (vonoprazan, a potassium-competitive acid blocker) in healthy m...
PMC8539938
core_pubmed_pmc
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation Abstract Abstract Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance....
PMC7877829
core_pubmed_pmc
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs Abstract Abstract The risk‐benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)‐related infectious coronavirus disease 2019 (COVID‐19) is complicated because ben...
PMC12968790
core_pubmed_pmc
Targeting mitochondrial quality control in osteoarthritis with GrpE-like 1-loaded synovial mesenchymal stromal/stem cell small extracellular vesicles
Targeting mitochondrial quality control in osteoarthritis with GrpE-like 1-loaded synovial mesenchymal stromal/stem cell small extracellular vesicles Abstract Recent studies have demonstrated that synovial mesenchymal stem cell-derived small extracellular vesicles (EVs) engineered to deliver GrpE-like 1 activated PTEN-...
PMC12239925
core_pubmed_pmc
Materials, Syntheses and Biomedical Applications of Nano-Quercetin Formulations: A Comprehensive Literature Review
Materials, Syntheses and Biomedical Applications of Nano-Quercetin Formulations: A Comprehensive Literature Review Abstract Abstract Quercetin (Qu), a naturally occurring flavonoid with potent antioxidant, anti-inflammatory, and anticancer properties, faces clinical limitations due to poor solubility, low stability, an...
PMC10370898
core_pubmed_pmc
SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study
SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study Abstract An effective approach to reverse multidrug resistance (MDR) is P-glycoprotein (P-gp, ABCB1) transport inhibition. To identify such molecular regul...
PMC5783144
core_pubmed_pmc
A review of the pharmacology and clinical efficacy of brivaracetam
A review of the pharmacology and clinical efficacy of brivaracetam Abstract Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher aff...
PMC6567057
core_pubmed_pmc
Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors
Pharmacokinetic, metabolic stability, plasma protein binding and CYP450s inhibition/induction assessment studies of N-(2-pyridylmethyl)-2-hydroxiymethyl-1-pyrrolidinyl-4-(3-chloro-4-methoxy-benzylamino)-5-pyrimidine-carboxamide as potential type 5 phosphodiesterase inhibitors Abstract ABSTRACT N-(2-pyridylmethyl)-2-hyd...
PMC12579685
core_pubmed_pmc
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic–Based Strategies
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic–Based Strategies Abstract Introduction Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with...
PMC3309646
core_pubmed_pmc
Preparation of Evodiamine Solid Dispersions and Its Pharmacokinetics
Preparation of Evodiamine Solid Dispersions and Its Pharmacokinetics Abstract In order to increase the dissolution rate and bioavailability, solid dispersions of evodiamine in PVP K 30 with different enriched samples of evodiamine to PVP K 30 ratios were prepared by solvent method. Our studies showed that the dissoluti...
PMC5845165
core_pubmed_pmc
Pharmacokinetic Study of 7 Compounds Following Oral Administration of Fructus Aurantii to Depressive Rats
Pharmacokinetic Study of 7 Compounds Following Oral Administration of Fructus Aurantii to Depressive Rats Abstract Abstract In the present study, the pharmacokinetics of multi-components (naringenin, nobiletin, meranzin hydrate, narirutin, naringin, hesperidin, and neohesperidin) were investigated in acute depressive r...
PMC4546378
core_pubmed_pmc
Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity
Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity Abstract Background E-52862 is a Sigma-1 receptor antagonist (S1RA) curre...
PMC11963541
core_pubmed_pmc
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers
Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers Abstract ABSTRACT Primaquine is the only widely available drug to prevent relapses of Plasmodium vivax malaria. Primaquine is underused because of concerns over oxidant hemolysis in glucose-...
PMC7796052
core_pubmed_pmc
Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign
Discovery of a Bradykinin B2 Partial Agonist Profile of Raloxifene in a Drug Repurposing Campaign Abstract Abstract Covid-19 urges a deeper understanding of the underlying molecular mechanisms involved in illness progression to provide a prompt therapeutical response with an adequate use of available drugs, including d...
PMC8212765
core_pubmed_pmc
Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs
Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs Abstract Abstract Objectives MSSA bloodstream infections (BSIs) are associated with considerable mortality. Data regarding therapeutic dru...
PMC11887333
core_pubmed_pmc
Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges
Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges Abstract Antibiotic resistance is currently one of the most significant threats to global public health and safety. And studies have found that over the next 25 years, 39 million people will die directly and 169 m...
PMC12836115
core_pubmed_pmc
Muscle mass correlates with rocuronium distribution volume and guides dose optimization in obese colorectal cancer patients
Muscle mass correlates with rocuronium distribution volume and guides dose optimization in obese colorectal cancer patients Abstract Abstract BACKGROUND Perioperative anesthesia management of obese patients presents significant challenges as traditional total body weight-based dosing fails to achieve optimal anesthetic...
PMC10535589
core_pubmed_pmc
Therapeutic Drug Monitoring (TDM) Implementation in Public Hospitals in Greece in 2003 and 2021: A Comparative Analysis of TDM Evolution over the Years
Therapeutic Drug Monitoring (TDM) Implementation in Public Hospitals in Greece in 2003 and 2021: A Comparative Analysis of TDM Evolution over the Years Abstract Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug concentrations. TDM can be used to determine treatment efficacy and to prevent the...
PMC10358706
core_pubmed_pmc
Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics
Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics Abstract Abstract Background: Both polypharmacy and potential drug-drug interactions (pDDIs), especially those at the pharmacokinetic level, are common in hospitalized patients and a...
PMC12895386
core_pubmed_pmc
Anesthesia Practices for Preterm Infants: A Survey in the Nordic Countries and Review of the Literature
Anesthesia Practices for Preterm Infants: A Survey in the Nordic Countries and Review of the Literature Abstract ABSTRACT Background Preterm infants are at increased risk of perioperative mortality and are among the most vulnerable patients anesthesiologists can encounter. The literature on anesthesia practice in prete...
PMC10649763
core_pubmed_pmc
Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools
Hepatic Impairment as a Risk Factor for Drug Safety: Suitability and Comparison of Four Liver Scores as Screening Tools Abstract Hepatic impairment (HI) influences the pharmacokinetics and pharmacodynamics of drugs and represents an important risk factor for drug safety. A reliable screening tool for HI identification ...
PMC11535297
core_pubmed_pmc
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies Abstract Abstract Bispecific antibodies represent a significant advancement in therapeutic antibody engineering, offering the ability to simultaneously target two distinct antigens. This dual-targeting capability enhances therapeutic efficacy, e...
PMC10509375
core_pubmed_pmc
Green synthesis of Piper nigrum copper-based nanoparticles: in silico study and ADMET analysis to assess their antioxidant, antibacterial, and cytotoxic effects
Green synthesis of Piper nigrum copper-based nanoparticles: in silico study and ADMET analysis to assess their antioxidant, antibacterial, and cytotoxic effects Abstract Abstract Nanobiotechnology is a popular branch of science that is gaining interest among scientists and researchers as it allows for the green manufac...
PMC6057540
core_pubmed_pmc
Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study Abstract Abstract Background Shorter duration of infusion of monoclonal antibody treatments may reduce treatment burden and improve he...
PMC12030455
core_pubmed_pmc
The Emergence of Psilocybin in Psychiatry and Neuroscience
The Emergence of Psilocybin in Psychiatry and Neuroscience Abstract Abstract Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s phar...
PMC10499420
core_pubmed_pmc
Anti‐inflammatory effects of dexamethasone in COVID ‐19 patients: Translational population PK / PD modeling and simulation
Anti‐inflammatory effects of dexamethasone in COVID ‐19 patients: Translational population PK / PD modeling and simulation Abstract Abstract Dexamethasone (DEX) given at a dose of 6 mg once‐daily for 10 days is a recommended dosing regimen in patients with coronavirus disease 2019 (COVID‐19) requiring oxygen therapy. W...
PMC11442000
core_pubmed_pmc
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections Abstract Abstract Background Temocillin is increasingly considered as an alternative to carbapenems. However, there is no consensus on optimal dosing strategies and limited data on temocilli...
PMC6754125
core_pubmed_pmc
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) Abstract Abstract Background The global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treatment is limited by lack of knowledge on use in pregnancy. Her...
PMC5890854
core_pubmed_pmc
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers Abstract Objectives To compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor monoclonal antibody in development for SLE, i...
PMC12916759
core_pubmed_pmc
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection Abstract Abstract Herein we report the development of novel covalent inhibitors of the SARS-CoV-2 main protease (Mpro). The developed compounds VPC285785 and VPC285786 demonstrated moderat...
PMC9778400
core_pubmed_pmc
Construction of an MLR-QSAR Model Based on Dietary Flavonoids and Screening of Natural α-Glucosidase Inhibitors
Construction of an MLR-QSAR Model Based on Dietary Flavonoids and Screening of Natural α-Glucosidase Inhibitors Abstract Abstract Postprandial hyperglycemia can be reduced by inhibiting α-glucosidase activity. Common α-glucosidase inhibitors such as acarbose may have various side effects. Therefore, it is important to ...
PMC7568551
core_pubmed_pmc
A novel assay to measure calcification propensity: from laboratory to humans
A novel assay to measure calcification propensity: from laboratory to humans Abstract Abstract Cardiovascular calcification (CVC) contributes to morbidity and mortality in patients undergoing dialysis. We examined the pharmacodynamic effects of SNF472, a calcification inhibitor, on plasma calcium phosphate crystallizat...
PMC6825008
core_pubmed_pmc
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer Abstract Abstract This study determined individual optimal amrubicin doses for Japanese patients with lung cancer after platinum‐based treatment. We carried out population pharmacokinetic and pharmacodynamic modelin...
PMC8528265
core_pubmed_pmc
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma Abstract Abstract Background There is an urgent need for additional therapies to treat recurrent glioblastoma (GBM). Preclinical studies suggest that high dose macitentan, an oral d...
PMC11079524
core_pubmed_pmc
The baicalein amorphous solid dispersion to enhance the dissolution and bioavailability and effects on growth performance, meat quality, antioxidant capacity and intestinal flora in Taihang chickens
The baicalein amorphous solid dispersion to enhance the dissolution and bioavailability and effects on growth performance, meat quality, antioxidant capacity and intestinal flora in Taihang chickens Abstract Baicalein ( BAI ) is a natural flavonoid with antioxidant, antitumor and antibacterial properties. However, the ...
PMC11683673
core_pubmed_pmc
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment Abstract ABSTRACT Aim This study aimed to determine the maximum tolerated dose (MTD) of the urokinase plasminogen activator (uPA) inhibitor upamostat (LH011) in combin...
PMC12641067
core_pubmed_pmc
Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters Abstract Endogenous biomarkers for drug transporters are an emerging tool for the assessment of transporter‐mediated drug–drug interactions (DDI). Glycochenodeoxycholic acid...
PMC6676270
core_pubmed_pmc
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy
Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy Abstract Abstract Extensive data support the safety of direct oral anticoagulants compared with vitamin K antagonists in patients with non‐valvular atrial fibrillation, leading to a significantly increase in the use of t...
PMC10787778
core_pubmed_pmc
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors Abstract Abstract Background VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvi...
PMC6009891
core_pubmed_pmc
Novel series of 1,2,4-trioxane derivatives as antimalarial agents
Novel series of 1,2,4-trioxane derivatives as antimalarial agents Abstract Abstract Among three series of 1,2,4-trioxane derivatives, five compounds showed good in vitro antimalarial activity, three compounds of which exhibited better activity against P. falciparum resistant (RKL9) strain than the sensitive (3D7) one. ...
PMC5105357
core_pubmed_pmc
Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs
Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs Abstract Abstract Purpose: To examine the pharmacokinetic characteristics of sustained-release dexamethasone depots in two separate canine studies. Methods: Dexamethasone depots loaded with a clinically representative (0.4 mg) dose (DEXT...
PMC7608064
core_pubmed_pmc
Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients
Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients Abstract ABSTRACT Chloroquine is the first-line therapy against the asexual stages of Plasmodium vivax . There is a high variation of chloroquine plasma levels after therapeutic doses, which can lead to...
PMC10453147
core_pubmed_pmc
Sex Differences in Therapies against Myocardial Ischemia-Reperfusion Injury: From Basic Science to Clinical Perspectives
Sex Differences in Therapies against Myocardial Ischemia-Reperfusion Injury: From Basic Science to Clinical Perspectives Abstract Abstract Mortality from myocardial infarction (MI) has declined over recent decades, which could be attributed in large part to improved treatment methods. Early reperfusion is the cornersto...
PMC11267486
core_pubmed_pmc
Insights into the stereoisomerism of dihydroquercetin: analytical and pharmacological aspects
Insights into the stereoisomerism of dihydroquercetin: analytical and pharmacological aspects Abstract Abstract Dihydroquercetin (DHQ) is a representative of flavonoids that is available on the market as a food supplement and registered as an active pharmaceutical ingredient. The structure of this compound is character...
PMC9582183
core_pubmed_pmc
Maximum Entropy Technique and Regularization Functional for Determining the Pharmacokinetic Parameters in DCE-MRI
Maximum Entropy Technique and Regularization Functional for Determining the Pharmacokinetic Parameters in DCE-MRI Abstract Abstract This paper aims to solve the arterial input function (AIF) determination in dynamic contrast-enhanced MRI (DCE-MRI), an important linear ill-posed inverse problem, using the maximum entrop...
PMC6920897
core_pubmed_pmc
Interactions of 7,8-Dihydroxyflavone with Serum Albumin as well as with CYP2C9, CYP2C19, CYP3A4, and Xanthine Oxidase Biotransformation Enzymes
Interactions of 7,8-Dihydroxyflavone with Serum Albumin as well as with CYP2C9, CYP2C19, CYP3A4, and Xanthine Oxidase Biotransformation Enzymes Abstract 7,8-dihydroxyflavone (DHF) is a flavone aglycone which has beneficial effects in several central nervous system diseases. Most of the pharmacokinetic properties of DHF...
PMC8182214
core_pubmed_pmc
Dual drug-induced aseptic meningoencephalitis: More than a suggestion
Dual drug-induced aseptic meningoencephalitis: More than a suggestion Abstract We present the case of a patient with a first single episode of a dual drug-induced aseptic mening (DIAM) due to amoxicillin and ibuprofen and a short review of updated literature. A 76-year-old man was admitted to our hospital with slowness...
PMC12123189
core_pubmed_pmc
Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections
Population Pharmacokinetic Analysis and Pharmacodynamic Evaluation of Sulbactam in Pediatric Patients: Dosing Suggestions for Acinetobacter baumannii Infections Abstract Abstract Background This study aims to develop a population pharmacokinetic (PK) model of sulbactam in pediatric patients using pooled data analysis, ...
PMC11247666
core_pubmed_pmc
A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease
A small‐molecule microtubule‐stabilizing agent safely reduces Aβ plaque and tau pathology in transgenic mouse models of Alzheimer's disease Abstract Abstract INTRODUCTION Intraneuronal inclusions composed of tau protein are found in Alzheimer's disease (AD) and other tauopathies. Tau normally binds microtubules (MTs), ...
PMC8145202
core_pubmed_pmc
Polymerized Albumin Receptor of Hepatitis B Virus for Evading the Reticuloendothelial System
Polymerized Albumin Receptor of Hepatitis B Virus for Evading the Reticuloendothelial System Abstract Various strategies, such as optimization of surface chemistry, size, shape, and charge, have been undertaken to develop nanoparticles (NPs) as DDS (drug delivery system) nanocarriers for evading the reticuloendothelial...
PMC10978739
core_pubmed_pmc
Nano-radiopharmaceuticals as therapeutic agents
Nano-radiopharmaceuticals as therapeutic agents Abstract Abstract In recent years, there has been an increased interest in exploring the potential synergy between nanotechnology and nuclear medicine. The application of radioactive isotopes, commonly referred to as radiopharmaceuticals, is recognized in nuclear medicine...
PMC12965103
core_pubmed_pmc
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Intravenous Vancomycin in Intracranial Hemorrhage Patients with External Ventricular Drains: Implications for Dosing and Therapeutic Drug Monitoring
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Intravenous Vancomycin in Intracranial Hemorrhage Patients with External Ventricular Drains: Implications for Dosing and Therapeutic Drug Monitoring Abstract Purpose Vancomycin is frequently used to treat central nervous system (CNS) infections, yet its...
PMC10640690
core_pubmed_pmc
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial Abstract Abstract Background Dolutegravir (DTG), combined with a backbone of 2 nucleoside reverse transcriptase inhibitors, is currently the preferred first-line treatment for huma...
PMC5786750
core_pubmed_pmc
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function Abstract ABSTRACT Many antibiotics require dose adjustments in patients with renal impairment and/or in those undergoing hemodialysis. Omadacycline, the first aminomethylcycline antibiotic in late-stage clinical development, displays a...
PMC5836847
core_pubmed_pmc
Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension Abstract Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patient...
PMC4448465
core_pubmed_pmc
Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats
Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats Abstract Abstract Background The optimal chemotherapy route for non-small cell lung cancers involving the phrenic nerve and diaphragm is unclear. The pharmacokinetic properties of paclit...
PMC9345591
core_pubmed_pmc
Vancomycin area under the curve-guided monitoring in pediatric patients
Vancomycin area under the curve-guided monitoring in pediatric patients Abstract Abstract Objective: To assess the percentage of vancomycin area under the curve/minimum inhibitory concentration target attainment in pediatric patients after the empirical dose regimen and to demonstrate the applicability of this method f...
PMC5405979
core_pubmed_pmc
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats Abstract Abstract Background The aim of this study was to describe the joint pharmacokinetic-pharmacodynamic model and evaluate thermal antinocic...
PMC8718548
core_pubmed_pmc
Sedation, Analgesia, and Muscle Relaxation During VV-ECMO Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2): A Single-Center, Retrospective, Observational Study
Sedation, Analgesia, and Muscle Relaxation During VV-ECMO Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2): A Single-Center, Retrospective, Observational Study Abstract Abstract Objective: The pharmacokinetics and pharmacodynamics of ECMO-supported sedative, analgesic, and musc...
PMC9344054
core_pubmed_pmc
Studies on Chemical Characterization of Ginkgo Amillaria Oral Solution and Its Drug–Drug Interaction With Piceatannol 3′- O - β -D-Glucopyranoside for Injection
Studies on Chemical Characterization of Ginkgo Amillaria Oral Solution and Its Drug–Drug Interaction With Piceatannol 3′- O - β -D-Glucopyranoside for Injection Abstract Abstract Ginkgo Amillaria oral solution (GAO) is commonly used for the treatment of cardiovascular and cerebrovascular diseases in China. Piceatannol-...
PMC11832584
core_pubmed_pmc
The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice
The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice Abstract Abstract Aims/hypothesis Metformin is an important first-line treatment for type 2 diabetes and acts by increasing the body’s ability to dispose of glucose. Me...
PMC7110358
core_pubmed_pmc
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile Abstract Despite the weak clinical efficacy of TRAIL death receptor agonists, a search is under way for new agents that more efficiently activate apoptot...
PMC7752525
core_pubmed_pmc
The Role of Stress and Genital Immunity in Sexual Trauma and HIV Susceptibility Among Adolescent Girls and Adult Women (The THRIVE Study): Protocol for a Longitudinal Case-Control Study
The Role of Stress and Genital Immunity in Sexual Trauma and HIV Susceptibility Among Adolescent Girls and Adult Women (The THRIVE Study): Protocol for a Longitudinal Case-Control Study Abstract Background The relationship between sexual violence and HIV risk has been extensively documented through social and behaviora...
PMC5399046
core_pubmed_pmc
Psychomotor effect differences between l -methamphetamine and d -methamphetamine are independent of murine plasma and brain pharmacokinetics profiles
Psychomotor effect differences between l -methamphetamine and d -methamphetamine are independent of murine plasma and brain pharmacokinetics profiles Abstract Abstract l -Methamphetamine has been occasionally referred to as a stimulant similar to d -methamphetamine, probably owing to insufficient comparative studies. H...
PMC8359491
core_pubmed_pmc
Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors
Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors Abstract Abstract Nivolumab 240 mg every 2 weeks is approved in China by the National Medical Product Agency for squamous cell carcinoma of the head and neck and gastric cancer, based on popu...
PMC3629222
core_pubmed_pmc
Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis
Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis Abstract Objectives Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, ...
PMC4334335
core_pubmed_pmc
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors Abstract Abstract IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors associated with interpatient varia...
PMC9907520
core_pubmed_pmc
Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria
Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria Abstract Abstract Background Lassa fever is endemic in large parts of West Africa. The recommended antiviral treatment is ribavirin. Two treatment regimens are cur...
PMC8614466
core_pubmed_pmc
PK/PD Analysis by Nonlinear Mixed-Effects Modeling of a Marbofloxacin Dose Regimen for Treatment of Goat Mastitis Produced by Coagulase-Negative Staphylococci
PK/PD Analysis by Nonlinear Mixed-Effects Modeling of a Marbofloxacin Dose Regimen for Treatment of Goat Mastitis Produced by Coagulase-Negative Staphylococci Abstract Abstract Simple Summary Coagulase-negative staphylococci are main pathogens that produce goat mastitis. Marbofloxacin is a third-generation fluoroquinol...
PMC9894594
core_pubmed_pmc
Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear
Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear Abstract Abstract Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report insulin pharmacodynamic (PD) and pharmacokinetic (PK) data ex...
PMC5322882
core_pubmed_pmc
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells Abstract Abstract Ethanol consumption is negatively associated with antiretroviral therapy (ART) adherence and general health in HIV positive individuals. Previously, we d...
PMC3218710
core_pubmed_pmc
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings Abstract Abstract The vast majority of people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome reside in the developing world, in settings characterized by limited hea...
PMC8070437
core_pubmed_pmc
The Impact of Dextran Sodium Sulfate-Induced Gastrointestinal Injury on the Pharmacokinetic Parameters of Donepezil and Its Active Metabolite 6- O -desmethyldonepezil, and Gastric Myoelectric Activity in Experimental Pigs
The Impact of Dextran Sodium Sulfate-Induced Gastrointestinal Injury on the Pharmacokinetic Parameters of Donepezil and Its Active Metabolite 6- O -desmethyldonepezil, and Gastric Myoelectric Activity in Experimental Pigs Abstract Gastrointestinal side effects of donepezil, including dyspepsia, nausea, vomiting or diar...
PMC11720699
core_pubmed_pmc
Developing Allosteric Chaperones for GBA1 -Associated Disorders—An Integrated Computational and Experimental Approach
Developing Allosteric Chaperones for GBA1 -Associated Disorders—An Integrated Computational and Experimental Approach Abstract Abstract Mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are associated with Gaucher disease and increased risk of Parkinson’s disease. This study des...
PMC8233906
core_pubmed_pmc
Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin ® LA
Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin ® LA Abstract Triptorelin acetate was encapsulated into silica microparticles by spray-drying a mixture of colloidal silica sol and triptorelin acetate solution. The resulting microparticles were then combined wi...
PMC12969485
core_pubmed_pmc
Evaluation of the management of high-risk obstetric patients living with epilepsy: A retrospective study from KwaZulu-Natal, South Africa
Evaluation of the management of high-risk obstetric patients living with epilepsy: A retrospective study from KwaZulu-Natal, South Africa Abstract Background Epilepsy affects approximately 60 million individuals worldwide, with women comprising nearly 50% of the cases. Physiological changes during pregnancy can alter a...
PMC10322778
core_pubmed_pmc
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates Abstract Background People living with HIV may present co-morbidities requiring the initiation and subsequently the discontinuation of medications wit...
PMC8646516
core_pubmed_pmc
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study Abstract Abstract This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (...
PMC9967190
core_pubmed_pmc
A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA in Plasma, CSF and Tissue Samples
A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA in Plasma, CSF and Tissue Samples Abstract Therapeutic oligonucleotides, such as antisense oligonucleotide (ASO) and small interfering RNA (siRNA), are a new class of therapeutics rapidly growing in drug discovery and development. A sensitive and re...
PMC9311154
core_pubmed_pmc
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study Abstract Abstract Aim To evaluate BAY 2433334, an oral activated factor XI (FXIa) inhibitor, in volunteers. Methods Phase 1 study of healthy men at a Germa...
PMC12677076
core_pubmed_pmc
Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients
Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients Abstract Summary Background We aimed to provide pharmacokinetic-pharmacodynamic (PK/PD) rationale for selecting the o...
PMC12491760
core_pubmed_pmc
Pharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft‐Versus‐Host Disease After Pediatric Liver Transplantation
Pharmacokinetic Monitoring of JAK Inhibitor and Tacrolimus for Safe and Effective Management of Graft‐Versus‐Host Disease After Pediatric Liver Transplantation Abstract ABSTRACT Background and Aim Though liver transplantation (LT) is effective for pediatric patients with end‐stage liver disease, it is associated with c...
PMC11743202
core_pubmed_pmc
Quantification and prediction of human fetal (-)-Δ 9 -tetrahydrocannabinol/(±)-11-OH-Δ 9 -tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity
Quantification and prediction of human fetal (-)-Δ 9 -tetrahydrocannabinol/(±)-11-OH-Δ 9 -tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity Abstract Abstract Prenatal cannabis use is associated with neurodevelopmental deficits, likely due to exposure to the psychoactive cannabinoid, (-)-Δ...
PMC9967583
core_pubmed_pmc
Does Aging Have an Impact on Vitamin C Status and Requirements? A Scoping Review of Comparative Studies of Aging and Institutionalisation
Does Aging Have an Impact on Vitamin C Status and Requirements? A Scoping Review of Comparative Studies of Aging and Institutionalisation Abstract Abstract The global healthcare burden of an aging population continues to increase, with nearly a quarter of the total global burden of disease attributable to people aged ≥...
PMC4532972
core_pubmed_pmc
A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery
A Randomized Clinical Trial of Nefopam versus Ketorolac Combined With Oxycodone in Patient-Controlled Analgesia after Gynecologic Surgery Abstract Abstract Objectives: Nefopam is a centrally-acting non-opioid analgesic, which has no effect on bleeding time and platelet aggregation. There has been no study about nefopam...
PMC10232915
core_pubmed_pmc
Multifunctional nanostructures: Intelligent design to overcome biological barriers
Multifunctional nanostructures: Intelligent design to overcome biological barriers Abstract Over the past three decades, nanoscience has offered a unique solution for reducing the systemic toxicity of chemotherapy drugs and for increasing drug therapeutic efficiency. However, the poor accumulation and pharmacokinetics ...
PMC5384948
core_pubmed_pmc
Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment
Levodopa/carbidopa microtablets in Parkinson’s disease: a study of pharmacokinetics and blinded motor assessment Abstract Abstract Background Motor function assessments with rating scales in relation to the pharmacokinetics of levodopa may increase the understanding of how to individualize and fine-tune treatments. Obj...
PMC7907604
core_pubmed_pmc
Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients—A Systematic Review
Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients—A Systematic Review Abstract Abstract Purpose: Enalapril has an established safety and efficacy in adults and is used in hypertension, heart failure, and renal failure. In pediatric patients, enalapril is labeled for children with hypertension...
PMC11754916
core_pubmed_pmc
Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis
Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis Abstract The COVID-19 pandemic caused by SARS-CoV-2 continues to pose a major challenge to global health. Targeting the main protease of the virus (Mpro), which is essential for viral replic...